医学
弥漫性大B细胞淋巴瘤
内科学
国际预后指标
肿瘤科
淋巴瘤
预测模型
回顾性队列研究
美罗华
生存分析
比例危险模型
危险系数
化疗
总体生存率
队列
存活率
作者
Ying Yang,Zhuogang Liu,Guo-Jun Zhang,Hongtao Wang
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-08-05
卷期号:17 (32): 4299-4306
标识
DOI:10.2217/fon-2020-1073
摘要
Aim: To identify risk factors and establish a concise prognostic scoring system in patients with diffuse large B-cell lymphoma (DLBCL). Methods: A total of 131 DLBCL patients were enrolled with long-term follow-up who were treated in Shengjing Hospital of the China Medical University. The relationship between clinical parameters and outcomes was analyzed. Results: Multivariate analysis showed that patient age, BMI, CA125 and rituximab application were independent risk factors. Thereafter, a concise scoring system was established, and the new system could identify high-risk patients (p < 0.0001). The patients were divided into three groups: low-risk, medium-risk and high-risk groups. There were significant differences among different groups on overall survival and progression-free survival by log-rank test (p < 0.05). Conclusion: Old age, low BMI, high CA125 and no rituximab application were independent risk factors for DLBCL. The new established prognostic score system, which includes all the risk factors, could identify high-risk patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI